Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

Phyu Aung, MD, PhD, FCAP, a dermatopathologist, discusses key challenges in diagnosing and treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Definitive diagnosis is difficult given BPDCN’s heterogeneous features and frequent skin and CNS involvement. Recent advances have utilized immunophenotyping and targeted CD123, which is overexpressed on BPDCN cells. However, resistance develops with CD123 monotherapy. She notes that while testing aids BPDCN insights, more prognostic markers are needed, and emphasizes that continued cross-disciplinary research is critical to better outcomes.

EP: 1.Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm

EP: 2.BPDCN: A Multidisciplinary Approach to Diagnosis and Treatment

EP: 3.Pivekimab Sunirine: A Novel CD123 ADC Showing Promise for BPDCN

Now Viewing

EP: 4.Advances in Diagnosis and Targeted Therapies for BPDCN from an Expert Dermatopathologist

EP: 5.Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future Potential

Related Videos